By accepting you will be accessing a service provided by a third-party external to https://mschristian.org/

Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced disability Progression in Multiple Sclerosis


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
– Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after six and a half years of Ocrevus treatment compared with patients who started Ocrevus after the double-blind period –
– Interim analysis of Phase IIIb study shows 87% of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to Ocrevus –
– Separate analysis from same study showed greater patient satisfaction with Ocrevus after one year on treatment –
– More than 120,000 people have been treated with Ocrevus globally, in clinical trial and real-world settings; data continue to show a consistent and favorable benefit-risk profile –
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® (Ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and Primary Progressive MS (PPMS). These results suggest earlier treatment with Ocrevus reduced the risk of disability progression and this effect was sustained over time. Additionally, new safety data as of January 2019 were announced, representing 4,611 patients with RMS and PPMS and 14,329 patient years of exposure to Ocrevus, across all Ocrevus clinical trials, and remain consistent with the medicine’s favorable benefit-risk profile. Findings were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm.
“The effect of MS therapies on progression – not just relapses – is very important to help reduce the impact of the disease on the daily lives of people with MS and their families,” said Professor Gavin Giovannoni, Consultant Neurologist at Barts and the London School of Medicine and Dentistry. “The Ocrevus data at ECTRIMS highlight that the benefit of delaying, and possibly preventing, disability progression is greater when the treatment is used earlier in the disease course for both relapsing and Primary Progressive forms of MS. These data support the aphorism, ‘time really is brain and spinal cord in Multiple Sclerosis.'”
In the OPERA OLE, the proportion of RMS patients with 24-week confirmed disability progression (CDP) was lower for those treated with continuous Ocrevus (total of six years on Ocrevus) compared with patients who switched to Ocrevus after two years of Interferon Beta-1a treatment in the double-blind period (total of four years on Ocrevus) (19% vs. 24%; p
Original author: Stuart
Genmab A/S (GMAB) Detailed Results from Phase III ...
#ECTRIMS2019 - Transplanting MSCs Safe, Helps Stop...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Friday, 07 August 2020

Captcha Image

MSChristian.org RSS Statement

Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.